Methods of delivery of cetyl myristoleate
AssigneeCG and Associates
InventorsGary Lord, Carol Lytle
Life of this patent
Estimating the term…
Abstract
The invention provides novel and advantageous delivery devices for compositions of cetyl myristoleate. The delivery devices include transdermal delivery devices, suppositories, enteric coatings, and microencapsulation. Further provided are methods of treating diseases using the disclosed delivery devices. Diseases that can be treated with the devices include, but are not limited to, diseases associated with the inflammation of tissues, diseases associated with inflammatory conditions affecting joints, and autoimmune diseases.
Claims27
A transdermal delivery device for the delivery of cetyl myristoleate wherein the transdermal delivery device contains between 1 mg and 3000 mg of cetyl myristoleate.
The transdermal delivery device wherein between 0.01 mg/kg/day and 10 mg/kg/day of cetyl myristoleate is delivered.
An oral medicament comprising cetyl myristoleate and an enteric coating, said coating being resistant to dissolution in the stomach but predisposed to dissolution in the intestine so as to prevent release of said cetyl myristoleate until said medicament is in the intestine.
An oral medicament comprising microencapsulated cetyl myristoleate, said microencapsulation being resistant to dissolution in the stomach but predisposed to dissolution in the intestine so as to prevent release of said cetyl myristoleate until said medicament is in the intestine.
A suppository for transrectal or transurethral delivery comprising cetyl myristoleate in combination with a physiologically acceptable solid carrier that is meltable at human or animal body temperature.
Dependencies are inferred from the claim text.